The abstract is read at the publisher; the summary is JClub's.
In the DECISION randomized, double-blind trial of 1,001 symptomatic chronic heart failure patients with LVEF ≤50%, low-dose digoxin did not significantly reduce the composite worsening-heart-failure/cardiovascular-mortality endpoint (rate ratio 0.81, P=0.133).
- Why it matters: Digoxin’s role in contemporary heart failure care is unclear, and prior suggestions of benefit lacked rigorous randomized evidence.
- What they did: Patients were randomized to low-dose digoxin or placebo, targeting serum digoxin 0.5–0.9 ng ml−1, and followed for a median of 36.5 months.
- The result: Primary-outcome events occurred in 131/500 vs 152/501 patients (238 vs 291 events), with no significant differences in worsening heart failure events (rate ratio 0.76) or cardiovascular mortality (hazard ratio 0.93).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.